APO RESEARCH · REPORT
Blood Product
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.
Product & engineering
Understand the product.
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.
Selected research
Industry Research
Blood Product Industry Research Report 2026
Market perspective
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.
The major players in global blood product market include Takeda, CSL, etc. The top 3 players occupy about 60% shares of the global market. North America and Europe are main markets, they occupy about 65% of the global market.
Report Scope
Read the full market overview
This report quantifies the global Blood Product market in terms of revenue (US$ million) and, where applicable, service volume (K Bottles), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Bottles) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Blood Product.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Blood Product Market by Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
Shanghai RAAS
China Biologic Products
Hualan Biological Engineering Inc.
Beijing Tiantan Biological Products Corp
Pacific Shuanglin
Boya Bio-Pharmaceutical
Paisi Feike Biology Pharmacy Co., Ltd.
Xinjiang Deyuan Bioengineering
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Shenzhen Weiguang
Shanxi Kangbao
Nanyue Biopharming Corporation Ltd
Blood Product Segment by Type
Albumin
Immunoglobulin
Clotting Factor
Others
Blood Product Segment by Application
Bleeding Wound
Immunodeficiency
HBV
Tetanus
Rabies
Hemophilia
Others
Blood Product Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Product and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Product.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Blood Product companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Albumin
- Immunoglobulin
- Clotting Factor
- Others
Applications
- Bleeding Wound
- Immunodeficiency
- HBV
- Tetanus
- Rabies
- Hemophilia
- Others
Companies covered
- Takeda
- CSL
- Grifols
- Octapharma
- Kedrion
- LFB Group
- Biotest
- BPL
- Shanghai RAAS
- China Biologic Products
- Hualan Biological Engineering Inc.
- Beijing Tiantan Biological Products Corp
- Pacific Shuanglin
- Boya Bio-Pharmaceutical
- Paisi Feike Biology Pharmacy Co., Ltd.
- Xinjiang Deyuan Bioengineering
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- Shenzhen Weiguang
- Shanxi Kangbao
- Nanyue Biopharming Corporation Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Blood Product by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Albumin
- 2.2.3 Immunoglobulin
- 2.2.4 Clotting Factor
- 2.2.5 Others
- 2.3 Blood Product by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Bleeding Wound
- 2.3.3 Immunodeficiency
- 2.3.4 HBV
- 2.3.5 Tetanus
- 2.3.6 Rabies
- 2.3.7 Hemophilia
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Blood Product Breakdown Data by Type
- 3.1 Global Blood Product Historic Market Size by Type (2021-2026)
- 3.2 Global Blood Product Forecasted Market Size by Type (2027-2032)
4 Blood Product Breakdown Data by Application
- 4.1 Global Blood Product Historic Market Size by Application (2021-2026)
- 4.2 Global Blood Product Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Blood Product Market Perspective (2021-2032)
- 5.2 Global Blood Product Growth Trends by Region
- 5.2.1 Global Blood Product Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Blood Product Historic Market Size by Region (2021-2026)
- 5.2.3 Blood Product Forecasted Market Size by Region (2027-2032)
- 5.3 Blood Product Market Dynamics
- 5.3.1 Blood Product Industry Trends
- 5.3.2 Blood Product Market Drivers
- 5.3.3 Blood Product Market Challenges
- 5.3.4 Blood Product Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Blood Product Players by Revenue
- 6.1.1 Global Top Blood Product Players by Revenue (2021-2026)
- 6.1.2 Global Blood Product Revenue Market Share by Players (2021-2026)
- 6.2 Global Blood Product Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Blood Product Head Office and Area Served
- 6.4 Global Blood Product Players, Product Type & Application
- 6.5 Global Blood Product Manufacturers Established Date
- 6.6 Global Blood Product Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Blood Product Market Size (2021-2032)
- 7.2 North America Blood Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Blood Product Market Size by Country (2021-2026)
- 7.4 North America Blood Product Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Blood Product Market Size (2021-2032)
- 8.2 Europe Blood Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Blood Product Market Size by Country (2021-2026)
- 8.4 Europe Blood Product Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Blood Product Market Size (2021-2032)
- 9.2 Asia-Pacific Blood Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Blood Product Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Blood Product Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Blood Product Market Size (2021-2032)
- 10.2 South America Blood Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Blood Product Market Size by Country (2021-2026)
- 10.4 South America Blood Product Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Blood Product Market Size (2021-2032)
- 11.2 Middle East & Africa Blood Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Blood Product Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Blood Product Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Blood Product Business (2021-2026)
- 12.1.4 Takeda Blood Product Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 CSL
- 12.2.1 CSL Company Information
- 12.2.2 CSL Business Overview
- 12.2.3 CSL Revenue in Blood Product Business (2021-2026)
- 12.2.4 CSL Blood Product Product Portfolio
- 12.2.5 CSL Recent Developments
- 12.3 Grifols
- 12.3.1 Grifols Company Information
- 12.3.2 Grifols Business Overview
- 12.3.3 Grifols Revenue in Blood Product Business (2021-2026)
- 12.3.4 Grifols Blood Product Product Portfolio
- 12.3.5 Grifols Recent Developments
- 12.4 Octapharma
- 12.4.1 Octapharma Company Information
- 12.4.2 Octapharma Business Overview
- 12.4.3 Octapharma Revenue in Blood Product Business (2021-2026)
- 12.4.4 Octapharma Blood Product Product Portfolio
- 12.4.5 Octapharma Recent Developments
- 12.5 Kedrion
- 12.5.1 Kedrion Company Information
- 12.5.2 Kedrion Business Overview
- 12.5.3 Kedrion Revenue in Blood Product Business (2021-2026)
- 12.5.4 Kedrion Blood Product Product Portfolio
- 12.5.5 Kedrion Recent Developments
- 12.6 LFB Group
- 12.6.1 LFB Group Company Information
- 12.6.2 LFB Group Business Overview
- 12.6.3 LFB Group Revenue in Blood Product Business (2021-2026)
- 12.6.4 LFB Group Blood Product Product Portfolio
- 12.6.5 LFB Group Recent Developments
- 12.7 Biotest
- 12.7.1 Biotest Company Information
- 12.7.2 Biotest Business Overview
- 12.7.3 Biotest Revenue in Blood Product Business (2021-2026)
- 12.7.4 Biotest Blood Product Product Portfolio
- 12.7.5 Biotest Recent Developments
- 12.8 BPL
- 12.8.1 BPL Company Information
- 12.8.2 BPL Business Overview
- 12.8.3 BPL Revenue in Blood Product Business (2021-2026)
- 12.8.4 BPL Blood Product Product Portfolio
- 12.8.5 BPL Recent Developments
- 12.9 Shanghai RAAS
- 12.9.1 Shanghai RAAS Company Information
- 12.9.2 Shanghai RAAS Business Overview
- 12.9.3 Shanghai RAAS Revenue in Blood Product Business (2021-2026)
- 12.9.4 Shanghai RAAS Blood Product Product Portfolio
- 12.9.5 Shanghai RAAS Recent Developments
- 12.10 China Biologic Products
- 12.10.1 China Biologic Products Company Information
- 12.10.2 China Biologic Products Business Overview
- 12.10.3 China Biologic Products Revenue in Blood Product Business (2021-2026)
- 12.10.4 China Biologic Products Blood Product Product Portfolio
- 12.10.5 China Biologic Products Recent Developments
- 12.11 Hualan Biological Engineering Inc.
- 12.11.1 Hualan Biological Engineering Inc. Company Information
- 12.11.2 Hualan Biological Engineering Inc. Business Overview
- 12.11.3 Hualan Biological Engineering Inc. Revenue in Blood Product Business (2021-2026)
- 12.11.4 Hualan Biological Engineering Inc. Blood Product Product Portfolio
- 12.11.5 Hualan Biological Engineering Inc. Recent Developments
- 12.12 Beijing Tiantan Biological Products Corp
- 12.12.1 Beijing Tiantan Biological Products Corp Company Information
- 12.12.2 Beijing Tiantan Biological Products Corp Business Overview
- 12.12.3 Beijing Tiantan Biological Products Corp Revenue in Blood Product Business (2021-2026)
- 12.12.4 Beijing Tiantan Biological Products Corp Blood Product Product Portfolio
- 12.12.5 Beijing Tiantan Biological Products Corp Recent Developments
- 12.13 Pacific Shuanglin
- 12.13.1 Pacific Shuanglin Company Information
- 12.13.2 Pacific Shuanglin Business Overview
- 12.13.3 Pacific Shuanglin Revenue in Blood Product Business (2021-2026)
- 12.13.4 Pacific Shuanglin Blood Product Product Portfolio
- 12.13.5 Pacific Shuanglin Recent Developments
- 12.14 Boya Bio-Pharmaceutical
- 12.14.1 Boya Bio-Pharmaceutical Company Information
- 12.14.2 Boya Bio-Pharmaceutical Business Overview
- 12.14.3 Boya Bio-Pharmaceutical Revenue in Blood Product Business (2021-2026)
- 12.14.4 Boya Bio-Pharmaceutical Blood Product Product Portfolio
- 12.14.5 Boya Bio-Pharmaceutical Recent Developments
- 12.15 Paisi Feike Biology Pharmacy Co., Ltd.
- 12.15.1 Paisi Feike Biology Pharmacy Co., Ltd. Company Information
- 12.15.2 Paisi Feike Biology Pharmacy Co., Ltd. Business Overview
- 12.15.3 Paisi Feike Biology Pharmacy Co., Ltd. Revenue in Blood Product Business (2021-2026)
- 12.15.4 Paisi Feike Biology Pharmacy Co., Ltd. Blood Product Product Portfolio
- 12.15.5 Paisi Feike Biology Pharmacy Co., Ltd. Recent Developments
- 12.16 Xinjiang Deyuan Bioengineering
- 12.16.1 Xinjiang Deyuan Bioengineering Company Information
- 12.16.2 Xinjiang Deyuan Bioengineering Business Overview
- 12.16.3 Xinjiang Deyuan Bioengineering Revenue in Blood Product Business (2021-2026)
- 12.16.4 Xinjiang Deyuan Bioengineering Blood Product Product Portfolio
- 12.16.5 Xinjiang Deyuan Bioengineering Recent Developments
- 12.17 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- 12.17.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
- 12.17.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Business Overview
- 12.17.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Revenue in Blood Product Business (2021-2026)
- 12.17.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Blood Product Product Portfolio
- 12.17.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Developments
- 12.18 Shenzhen Weiguang
- 12.18.1 Shenzhen Weiguang Company Information
- 12.18.2 Shenzhen Weiguang Business Overview
- 12.18.3 Shenzhen Weiguang Revenue in Blood Product Business (2021-2026)
- 12.18.4 Shenzhen Weiguang Blood Product Product Portfolio
- 12.18.5 Shenzhen Weiguang Recent Developments
- 12.19 Shanxi Kangbao
- 12.19.1 Shanxi Kangbao Company Information
- 12.19.2 Shanxi Kangbao Business Overview
- 12.19.3 Shanxi Kangbao Revenue in Blood Product Business (2021-2026)
- 12.19.4 Shanxi Kangbao Blood Product Product Portfolio
- 12.19.5 Shanxi Kangbao Recent Developments
- 12.20 Nanyue Biopharming Corporation Ltd
- 12.20.1 Nanyue Biopharming Corporation Ltd Company Information
- 12.20.2 Nanyue Biopharming Corporation Ltd Business Overview
- 12.20.3 Nanyue Biopharming Corporation Ltd Revenue in Blood Product Business (2021-2026)
- 12.20.4 Nanyue Biopharming Corporation Ltd Blood Product Product Portfolio
- 12.20.5 Nanyue Biopharming Corporation Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst